Mast Therapeutics (MSTX) Reports In-Line Q4 Loss

Mast Therapeutics (NYSE: MSTX) reported Q4 EPS of ($0.06), in-line with the analyst estimate of ($0.06).

For earnings history and earnings-related data on Mast Therapeutics (MSTX) click here.

You May Also Be Interested In

• Investing.com’s stocks of the week
• Arbor Realty Trust (ABR) Tops Q2 EPS by 4c
• Affiliated Managers Group (AMG) Tops Q2 EPS by 43c